Senior Corporate Counsel, Contracts (Clinical Development)

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified checked Jun 7, 2026

Salary

$244K-$282K From the posting source checked Jun 20, 2026

401(k) match

Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$117,235 U.S. median for this role

Projected growth (BLS Employment Projections)

+2.6% - Average

124% above the BLS role benchmark for legal aggregate.

Matched to SOC 23-1011 - Legal aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function

Legal From the posting source checked Jun 20, 2026

Seniority

Senior From the posting source checked Jun 20, 2026

Schedule

Shift type

Not verified

Weekend work

Not verified

Company

Company stage

Late-stage From the posting source checked Jun 20, 2026

Equity

Offered Verified - SEC 10-K source checked Jun 20, 2026

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Senior Corporate Counsel, Contracts (Clinical Development) Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Corporate Counsel, Contracts (Clinical Development) will support the Company's clinical research and development activities by drafting, negotiating, and advising on a broad range of clinical and research-related agreements. This role partners closely with Clinical Development, Clinical Operations, Biometrics, Medical Affairs, Procurement, and Legal and Compliance teams to enable efficient and compliant execution of clinical programs. The ideal candidate has strong experience with clinical trial agreements and related contracts in a biotech or pharmaceutical setting, excellent judgment, and the ability to manage multiple priorities in a fast-paced environment. Key responsibilities include: - Draft, review, and negotiate a wide range of clinical development agreements, including: - Clinical Trial Agreements (CTAs). - Site agreements and amendments. - CRO, SMO, and vendor agreements. - Consulting agreements for investigators and key opinion leaders. - Data sharing, biometrics, and lab services agreements. - Advise internal

Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.